Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 141 - 150 of 166

Selected Filters:
19 August 2022

Implementation Science Questions for CAB for PrEP

This document outlines the key evidence gaps around cabotegravir (CAB) for PrEP that should be addressed when designing implementation research.

Research

Document
16 August 2022

Background Resources on Cabotegravir for PrEP

This document, produced by the MOSAIC consortium, provides a list of key resources on research and evidence for cabotegravir (CAB) for PrEP.

Research

Document
12 August 2022

A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP

AVAC’s Plan for Accelerating Access and Introduction of Injectable Cabotegravir (CAB) for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years…

Community/Advocacy

External Link
8 August 2022

Long-Acting Injectable Cabotegravir: Implementation science needed to advance this additional HIV prevention choice

In this article, the authors outline priority areas for implementation research needed to inform the effective scale-up of cabotegravir for PrEP.

Research

External Link
8 August 2022

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women

This press release provides an overview of the new findings from HPTN 084, a trial of the HIV Prevention Trials Network studying injectable cabotegravir for PrEP among cisgender women. The updated results show reductions in HIV incidence were sustained in the 12 months following unblinding and were presented at the AIDS 2022 conference in Montreal.

Research

External Link
5 August 2022

WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention

WHO guidelines, issued in 2022, recommend injectable cabotegravir (CAB) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. These guidelines provide considerations to support managers, policy makers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programs for injectable CAB for PrEP. It…

Normative Guidance/Policies

Document
4 August 2022

AVAC, BMGF, CIFF, MedAccess, Unitaid and ViiV Healthcare announce collaboration to catalyse more affordable access to long- acting injectable cabotegravir for HIV prevention

AVAC press release announcing a new collaboration focused on pricing, innovative funding mechanisms, tracking regulatory approvals, and ensuring the inclusion of civil society in key planning and decision making to speed access to injectable cabotegravir (CAB) for PrEP. Launched at the 24th International AIDS Conference, this collaboration includes AVAC, the Bill and Melinda Gates Foundation,…

Community/Advocacy

External Link
4 August 2022

ViiV and Medicines Patent Pool Sign Voluntary Licensing Agreement for Cabotegravir for PrEP

ViiV Healthcare and the Medicines Patent Pool (MPP) announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir for PrEP to help enable access in least developed, low-income, lower middle-income and Sub-Saharan African countries.

Service Delivery, Supply Chain Management

External Link
4 August 2022

Coordinating Implementation Science for CAB for PrEP

As implementation studies for injectable cabotegravir (CAB) for PrEP are being considered and as programs shift towards choice-based models for HIV prevention, there is a chance to correct for missed opportunities with oral PrEP rollout, understand client preferences and patterns of use, and ensure more effective coordination across geographies, populations, and projects. To facilitate this…

Research

Document
4 August 2022

BioPIC CAB for PrEP Study Compendium

This compendium provides detail on planned and ongoing studies related to landscaping, product introduction, introduction studies, and implementation research for Cabotegravir for PrEP and is a companion to the Implementation Study Tracker. If you would like to add your study to the compendium, please contact Catherine Verde Hashim.

Research

Presentation